Richard Lerner - Opko Health Independent Director
| OPK Stock | 478.70 7.60 1.61% |
Director
Dr. Richard Alan Lerner, M.D. serves as Independent Director of the Company. Dr. Lerner has served as a director of the Company since March 2007. Dr. Lerner was a private investor in companies for the past five years. Dr. Lerner served as President of The Scripps Research Institute, a private, nonprofit biomedical research organization, from 1986 until 2011 and is currently serving as an institute professor. Dr. Lerner is a member of numerous scientific associations, including the National Academy of Science and the Royal Swedish Academy of Sciences since 2007.
| Age | 79 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has return on total asset (ROA) of (0.0659) % which means that it has lost $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1867) %, meaning that it generated substantial loss on money invested by shareholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Yehoshua Ehrlich | Nice | 69 | |
| Estery GilozRan | Kamada | 44 | |
| Rimon BenShaoul | Nice | 74 | |
| Yehoshua Gleitman | Elbit Systems | 69 | |
| JeanMichel Halfon | Teva Pharmaceutical Industries | 67 | |
| Kalman Kaufman | Tower Semiconductor | 72 | |
| Dalia Rabin | Elbit Systems | 66 | |
| Jean Halfon | Teva Pharmaceutical Industries | 62 | |
| Ilan Flato | Tower Semiconductor | 61 | |
| Avraham Guzman | Tower Semiconductor | 79 | |
| Jonathan Hahn | Kamada | 32 | |
| Yoav Doppelt | Tower Semiconductor | 46 | |
| Ory Slonim | Teva Pharmaceutical Industries | 73 | |
| Asaf Frumerman | Kamada | N/A | |
| Galia Maor | Teva Pharmaceutical Industries | 73 | |
| Dan Propper | Teva Pharmaceutical Industries | 73 | |
| Sagi Kabla | Tower Semiconductor | 38 | |
| Joseph Cowan | Nice | 70 | |
| Dana Gross | Tower Semiconductor | 51 | |
| Perry Nisen | Teva Pharmaceutical Industries | 63 | |
| Roger Abravanel | Teva Pharmaceutical Industries | 71 | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Richard Lerner, Independent Director | ||
| Dmitry Kolosov, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, Pres Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.20) % | |||
| Current Valuation | 3.9 B | |||
| Shares Outstanding | 772.69 M | |||
| Shares Owned By Insiders | 45.87 % | |||
| Shares Owned By Institutions | 24.36 % | |||
| Price To Book | 0.63 X | |||
| Price To Sales | 2.78 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Opko Stock refer to our How to Trade Opko Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |